Zyflamend对实验性口腔癌前病变化学预防作用的研究  被引量:6

Chemopreventive effect of Zyflamend on DMBA-induced oral precancerous lesions in hamsters

在线阅读下载全文

作  者:李芳[1] 孙正[1] 吴洪儒[1] 陈晓欣 李宁[3] 

机构地区:[1]首都医科大学附属北京口腔医院 [2]美国North Carolina Central University [3]中国疾病预防控制中心营养与食品安全所

出  处:《北京口腔医学》2007年第2期61-64,共4页Beijing Journal of Stomatology

基  金:国家"十五"科技攻关计划(No.2004BA720A28)

摘  要:目的通过局部应用抗炎中药混合制剂Zyflamend,观察二甲基苯并蒽(7,12-dimethybenz[α]anthracene,DMBA)诱发金黄地鼠口腔癌前病变的化学预防作用。方法实验分5组:阴性对照组正常饲养;其余用0.5%的DMBA涂于左侧颊囊,每周3次,涂3周,再随机分为4组,阳性对照组不用药物治疗,其余3组用低、中、高浓度Zyflamend进行治疗,每周涂药3次,第4周末处死动物,处死前2h腹腔注射50mg/kg的5-溴脱氧尿嘧啶(5-bromo-deoxyuridine,BrdU)。取左侧颊囊进行组织病理学观察和BrdU免疫组化染色。结果低、中、高浓度Zyflamend治疗后,每平方毫米炎症细胞的数量分别为54.70±38.73、36.90±8.63和35.23±15.13,各组与阳性对照组(158.65±56.12)相比均有显著性差异(P<0.01);单纯增生的灶数分别为2.31±0.94,1.40±1.31和1.16±0.52,对照组为4.60±3.63;异常增生的灶数分别为2.10±1.78,1.80±0.94和1.03±0.97,对照组为3.47±2.03。中、高浓度治疗组BrdU增殖指数显著降低(P<0.01)。结论抗炎中药混合制剂Zyflamend对DMBA诱发的金黄地鼠口腔癌前病变具有一定的化学预防作用,其机制可能与抑制炎症和细胞增殖有关。Objective To study the preventive effect of a unique anti-inflammatory herbal preparation (Zyflamend) on 7,12-dimethylbenz[ α] anthracene(DMBA)-induced oral precancerous lesions in golden Syrian hamsters. Methods The hamsters were divided into five groups. While the negative control group was not treated, the other Syrian hamsters were applied with 0. 5% DMBA solution topically to the left cheek pouch three times per week for three consecutive weeks. After the last treatment of DMBA, the hamsters were divided into four groups at random. The positive group was not treated, the other groups received low, middle and high doses of Zyflamend respectively three times a week for four weeks. The animals were disposed of 4 weeks after the start of the experiment. They were injected with 5-bromo- 2'-deoxyuridine (BrdU) 50mg/kg before they were killed. The samples were collected for histopathology and BrdU immunohistochemisty. Results In low, middle and high doses of Zylqamend group, the number of inflammatory cells/ram2 was 54. 70 ± 38.73,36. 90 ± 8.63 and 35.23 ± 15. 13, respectively compared to the control group ( 158.65 ± 56. 12) (P 〈0. 01 ) ; the incidence of hyperplasia was 2 . 31 ±0. 94, 1.40 ± 1.31 and 1.16 ±0. 52, respectively compared to the control(4. 60 ± 3.63 ) , the incidence of dysplasia was 2. 10 ± 1.78,1.80 ± 0. 94 and 1.03 ± 0. 97, respectively compared to the control ( 3.47 ± 2. 03 ). The high dose of Zyflamend significantly decreased the incidence of hyperplasia and dysplasia (P 〈 0. 05). Middle and high doses of Zyflamend decreased the frequency of BrdU -index ( P 〈 0. 01 ). Conclusion Zyflamend, a unique anti-inflammatory herbal preparation, has some effect on the prevention of DMBA-induced oral precancerous lesions and such prevention may be related to the effect of anti-inflammation and the suppression of cell proliferation.

关 键 词:Zyflamend 口腔癌前病变 炎症 化学预防 

分 类 号:R739.8[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象